Abstract
Pityriasis Rubra Pilaris (PRP) is a rare inflammatory skin disease with highly variable clinical appearance. Treatment of PRP remains a challenge and has been mostly guided by case reports and case series. We report the first case of pityrisis rubra pilaris that is successfully treated with combination therapy of brodalumab and methotrexate.
Highlights
Pityriasis Rubra Pilaris (PRP) is a rare papulosquamous inflammatory dermatosis of unknown etiology that may affect skin, nails, and hair
We present the case of a patient with type I PRP who achieved complete resolution after initiation with combination therapy of brodalumab and methotrexate
The patient presented to our clinic with generalized erythematous-orange scaly patches with islands of sparing (Figure 1A). Based on his clinical presentation we diagnosed him as classic adult onset Pityriasis Rubra Pilaris (PRP)
Summary
Pityriasis Rubra Pilaris (PRP) is a rare papulosquamous inflammatory dermatosis of unknown etiology that may affect skin, nails, and hair. The condition mostly affects adults in their sixth or seventh decade of life with no predilection for genders and is subdivided into six different subtypes based on clinical features, age of onset and prognosis.[2,3] We present the case of a patient with type I (classic adult onset) PRP who achieved complete resolution after initiation with combination therapy of brodalumab and methotrexate. The patient presented to our clinic with generalized erythematous-orange scaly patches with islands of sparing (Figure 1A).
Sign-in/Register to view highlights & summary Sign-in/Register to access full text options 
Talk to us
Join us for a 30 min session where you can share your feedback and ask us any queries you have
Schedule a callDisclaimer: All third-party content on this website/platform is and will remain the property of their respective owners and is provided on "as is" basis without any warranties, express or implied. Use of third-party content does not indicate any affiliation, sponsorship with or endorsement by them. Any references to third-party content is to identify the corresponding services and shall be considered fair use under The CopyrightLaw.
